We are live on ! Find out more
PHXM

PHAXIAM Therapeutics S.A.. American Depositary Shares
PHXM

Delisted

PHXM was delisted on the 8th of March, 2024.

Back to rankings

7 hedge funds and large institutions have $51.6M invested in PHAXIAM Therapeutics S.A.. American Depositary Shares in 2018 Q2 according to their latest regulatory filings, with 1 funds opening new positions, increasing their positions, 2 reducing their positions, and 2 closing their positions.

New
Increased
Maintained
Reduced
Closed

13% less funds holding

Funds holding: 8 → 7 (-1)

46% less capital invested

Capital invested by funds: $96M → $51.6M (-$44.4M)

50% less first-time investments, than exits

New positions opened: 1 | Existing positions closed: 2

100% less repeat investments, than reductions

Existing positions increased: 0 | Existing positions reduced: 2

Holders
7
Holders Change
-1
Holders Change %
-12.5%
% of All Funds
0.16%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
1
Increased
–
Reduced
2
Closed
2
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
EC
EcoR1 Capital
California
+$2.89M

Top Sellers

Rank Fund Capital Flow
1
SFM
Sphera Funds Management
Israel
-$2.52M
2
BBA
Baker Bros. Advisors
New York
-$77K
3
Millennium Management
Millennium Management
New York
-$59.8K
4
EDRH
Edmond de Rothschild Holding
Switzerland
-$12K
Name Holding Trade Value Shares
Change 		Change in
Stake
BBA
1
Baker Bros. Advisors
New York
$34.5M -$77K -410 -0.1%
BI
2
BVF Inc
California
$7.21M – – –
NMC
3
NEA Management Company
Maryland
$6.98M – – –
EC
4
EcoR1 Capital
California
$1.73M +$2.89M +15,396 New
DG
5
Delek Group
Israel
$782K – – –
Millennium Management
6
Millennium Management
New York
$444K -$59.8K -318 -8%
UBS Group
7
UBS Group
Switzerland
$13K – – –
SFM
8
Sphera Funds Management
Israel
– -$2.52M -12,000 Closed
EDRH
9
Edmond de Rothschild Holding
Switzerland
– -$12K -57 Closed

PHXM Hedge Fund Activity: Q2 2018 in Review

7 of the 4,369 institutional investors tracked by Wall St. Rank reported a position in PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) for Q2 2018, worth a combined $51.6M — down 46% from $96M a quarter earlier.

Sellers outnumbered buyers: 2 funds closed out of PHXM and 1 opened new positions — a net loss of 1 holder — while 2 trimmed existing stakes and 0 added.

The largest buyer was EcoR1 Capital, opening a new position worth an estimated $2.89M. The largest seller was Sphera Funds Management, exiting entirely with an estimated $2.52M sold.

  • 7 institutional investors held PHAXIAM Therapeutics S.A.. American Depositary Shares (PHXM) as of Q2 2018, down from 8 in Q1 2018.
  • Funds reported $51.6M of PHAXIAM Therapeutics S.A.. American Depositary Shares stock for Q2 2018, down 46% quarter-over-quarter.
  • 1 fund opened new PHAXIAM Therapeutics S.A.. American Depositary Shares positions in Q2 2018 and 2 closed out, a net change of -1 holder.
  • The largest PHAXIAM Therapeutics S.A.. American Depositary Shares buyer in Q2 2018 was EcoR1 Capital, an estimated $2.89M added.
  • The largest PHAXIAM Therapeutics S.A.. American Depositary Shares seller in Q2 2018 was Sphera Funds Management, an estimated $2.52M sold.

Based on aggregated 13F filings for Q2 2018.